Individual Patient Compassionate Use of GX-I7

• Conditions: Glioblastoma; High Grade Glioma; Recurrent Glioblastoma; Melanoma; Advanced Cancer

• Registration Number: NCT04289155
• Lead Sponsor: Genexine, Inc.

Brief Summary

Compassionate use of GX-I7 for patients with serious life-threatening illness that have exhausted all available therapies, with no other therapy options.

Detailed Description

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Study Timeline

• Study First Submitted: 2020-02-26
• Study First Submitted QC: 2020-02-26
• Study First Posted: 2020-02-28
• Status Verified: 2022-03
• Last Update Submitted: 2022-03-02
• Last Update Posted: 2022-03-17

Recruitment & Eligibility

• Status: NO_LONGER_AVAILABLE
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Exclusion Criteria

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (1)

Kangnam St. Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of